Masayuki Tanahashi

Masayuki Tanahashi

Division Of Thoracic Surgery, Respiratory Disease Center, Seirei Mikatahara General Hospital, 3453, Mikatahara, Kita-Ku, Hamamatsu, 433-8105, Shizuoka, Japan

Direct Impact

Concepts for which Masayuki Tanahashi has direct influence:

lung cancer
limited resection
pd-l1 expression
late recurrence
induction chemoradiotherapy
lymphangitis carcinomatosa
centrosome amplification

External impact

Concepts related to the work of other authors for which Masayuki Tanahashi has influence:

pd-l1 expression
lung cancer
tissue microarrays
intratumor heterogeneity
immune microenvironment
chemotherapy response
copy number

Prominent publications by Masayuki Tanahashi

KOL-Index: 85 Thyroid transcription factor 1 (TTF1) located on chromosome band 14q13.3 is an oncogene and a suppressor gene in non-small cell lung cancer (NSCLC). The prognostic relevance of TTF1 copy number alterations (CNAs) and their association with TTF1 protein expression are poorly understood. Here, we assessed TTF1 CNAs and protein expression using microarrays in a cohort of 636 NSCLC, including ...
Known for
Prognostic Relevance | 171 Squamous Carcinoma | Number Ttf1 | Suppressor Gene
KOL-Index: 63 OBJECTIVES: Most patients with non-small cell lung cancer (NSCLC) are diagnosed at advanced stages where small biopsy specimens obtained through endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) are sometimes the only available samples for diagnosis. We aimed to determine whether EBUS-TBNA specimens are suitable for the evaluation of PD-L1 protein expression and ...
Known for
Cnas Protein | Specimens Primary | Expression Copy | Metastatic Sites
KOL-Index: 37 BACKGROUND: In this study, we analyzed the usefulness of adjuvant chemotherapy for non-small cell lung cancer based on the histoculture drug response assay (HDRA). METHODS: From September 2001 to December 2008, 65 patients with pathologic stage II or higher non-small cell lung cancer who underwent surgery received two-cycle HDRA-based adjuvant chemotherapy. Chemosensitivity to cisplatin, ...
Known for
Administered Hdra-Positive Drugs | Higher Non-Small Lung Cancer | 5-Year Disease-Free Survival Rate | Prediction-Nonsensitive
KOL-Index: 35 CD200, a member of the immunoglobulin superfamily, interacts with its receptor CD200R1 to modulate cancer immune microenvironments. Here, we explored the clinicopathological and prognostic implications of the CD200/CD200R1 axis in non-small-cell lung cancer (NSCLC) patients. We evaluated CD200/CD200R1 expression in the tumors and stroma of 632 NSCLC patients using immunohistochemistry. ...
Known for
Transient Knockdown | Prognostic Roles | Vitro Modulation | 632 Nsclc
KOL-Index: 26 The human YTH domain family (YTHDF) proteins are RNA-binding proteins that recognize N6-methyladenosine (m6A), facilitating various biological processes via m6A RNA modification. How these molecules associate with non-small-cell lung cancer (NSCLC) molecular mechanisms remain unclear. The protein expression levels of YTHDF1 and YTHDF2 in 603 cases of resected NSCLC were evaluated using ...
Known for
M6a Rna Modification | Prognostic Nsclc | Yth Domain Ythdf Proteins | Tumors Expressions
KOL-Index: 26 New reliable biomarkers are needed to predict the response to immune checkpoint inhibitors against programmed death-1 (PD-1) and its ligand (PD-L1), because PD-L1 expression on tumor cells has limited power for selecting patients who may benefit from such therapy. Here we investigated the significance of PD-L1 and PD-L2 gene copy number gains using fluorescence in situ hybridization as well ...
Known for
Smoking-Related Tumors | 2 Gene Copy Number | Pd-L1 Genomic Gains | Feasible Alternative Biomarker
KOL-Index: 25 R-spondin (RSPO) gene fusions have recently been discovered in a subset of human colorectal cancer (CRC) in the U.S. population; however, whether the fusion is recurrent in CRC arising in patients from the other demographic areas and whether it is specific for CRC remain uncertain. In this study, we examined 75 primary CRCs and 121 primary lung cancers in the Japanese population for ...
Known for
Demographic Areas | Lung Carcinomas | Cdx2 Lineage | Colorectal Cells
KOL-Index: 24 Human WDR62, which is localized in the cytoplasm including the centrosome, is known to be responsible for primary microcephaly; however, the role of WDR62 abnormality in cancers remains largely unknown. In this study, we aimed to reveal the pathological role of WDR62 abnormality in lung adenocarcinoma (LAC). We first examined the WDR62 mRNA expression level of LAC (n = 64) using a QRT-PCR ...
Known for
Wdr62 Mrna Expression Level | Wilcoxon | Cancer Genome Atlas | Overexpressed Lac
KOL-Index: 24 The recent discovery of mutations and fusions of oncokinase genes in a subset of lung cancers (LCs) is of considerable clinical interest, since LCs containing such mutations or fusion transcripts are reportedly sensitive to kinase inhibitors. To better understand the role of the recently identified fibroblast growth factor receptor 3 (FGFR3) mutations and fusions in pulmonary carcinogenesis, ...
Known for
Reverse Transcription-Polymerase Chain Reaction | Identified Fibroblast Growth Factor | Fgfr3-Baiap2l1 Fusion Transcripts | Lung Cancers
KOL-Index: 23 OBJECTIVES: Alterations in the MET gene, such as mutations and high-level amplification, are important drivers of non-small cell lung cancer (NSCLC). The efficacy of immune checkpoint inhibitors (ICIs) in lung cancer with MET abnormalities is unclear. We evaluate the potential relationship between MET alterations and the tumor immune microenvironment and PD-1/PD-L1 axis. MATERIAL AND ...
Known for
Met-Altered Adcs | Expression Assessed | 408 Adenocarcinoma Adc | Tils Altered

Division of Thoracic Surgery, Respiratory Disease Center, Seirei Mikatahara General Hospital, 3453, Mikatahara, Kita-ku, Hamamatsu, 433-8105, Shizuoka, Japan

https://www.g2.com/products/key-opinion-leaders-kols/reviews https://www.bbb.org/us/fl/doral/profile/data-analytics/key-opinion-leaders-0633-92023858 https://www.trustpilot.com/review/keyopinionleaders.com https://www.yelp.com/biz/key-opinion-leaders-miami


© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172